International Journal of Chronic Obstructive Pulmonary Disease

Cardiac Safety Tiotropium and Olodaterol

This Thematic Series describes the authors' detailed analyses of heart rate, 24-hr Holter electrocardiogram data and blood pressure from large clinical cohorts of patients with moderate-to-severe COPD receiving tiotropium and/or olodaterol as mono- or combination therapy. Overall, the analyses show that long-term administration of dual bronchodilation therapy is not associated with changes in heart rate or blood pressure and does not present any medically relevant effects on arrhythmias compared with monotherapies. Additionally, treatment with olodaterol or formoterol is not associated with arrhythmias or persistent increases in heart rate in patients with COPD.24 The conclusions from these extensive analyses support the findings of previously published monotherapy evaluations.